JP2021500349A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500349A5 JP2021500349A5 JP2020522016A JP2020522016A JP2021500349A5 JP 2021500349 A5 JP2021500349 A5 JP 2021500349A5 JP 2020522016 A JP2020522016 A JP 2020522016A JP 2020522016 A JP2020522016 A JP 2020522016A JP 2021500349 A5 JP2021500349 A5 JP 2021500349A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition
- composition according
- dose
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022186406A JP2023018062A (ja) | 2017-10-18 | 2022-11-22 | 抗ｃｄ４７剤ベースの卵巣癌療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573835P | 2017-10-18 | 2017-10-18 | |
| US62/573,835 | 2017-10-18 | ||
| PCT/US2018/056441 WO2019079548A1 (en) | 2017-10-18 | 2018-10-18 | OVARIAN CANCER THERAPY BASED ON ANTI-CD47 AGENT |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022186406A Division JP2023018062A (ja) | 2017-10-18 | 2022-11-22 | 抗ｃｄ４７剤ベースの卵巣癌療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021500349A JP2021500349A (ja) | 2021-01-07 |
| JP2021500349A5 true JP2021500349A5 (https=) | 2021-10-07 |
| JP7308191B2 JP7308191B2 (ja) | 2023-07-13 |
Family
ID=64267915
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020522016A Active JP7308191B2 (ja) | 2017-10-18 | 2018-10-18 | 抗ｃｄ４７剤ベースの卵巣癌療法 |
| JP2022186406A Pending JP2023018062A (ja) | 2017-10-18 | 2022-11-22 | 抗ｃｄ４７剤ベースの卵巣癌療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022186406A Pending JP2023018062A (ja) | 2017-10-18 | 2022-11-22 | 抗ｃｄ４７剤ベースの卵巣癌療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11802153B2 (https=) |
| EP (2) | EP3697817B1 (https=) |
| JP (2) | JP7308191B2 (https=) |
| KR (1) | KR102776457B1 (https=) |
| CN (2) | CN111247172B (https=) |
| AU (1) | AU2018351006B2 (https=) |
| CA (1) | CA3078253A1 (https=) |
| ES (2) | ES2932286T3 (https=) |
| PL (2) | PL3697817T3 (https=) |
| PT (2) | PT3697817T (https=) |
| SI (2) | SI3697817T1 (https=) |
| WO (1) | WO2019079548A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3402820T (pt) | 2016-01-11 | 2020-08-20 | Forty Seven Inc | Anticorpos monoclonais anti-cd47 quiméricos, de ratinho ou humanizados |
| JP7308191B2 (ja) | 2017-10-18 | 2023-07-13 | フォーティ セブン， インコーポレイテッド | 抗ｃｄ４７剤ベースの卵巣癌療法 |
| CN111699005A (zh) | 2018-02-12 | 2020-09-22 | 四十七公司 | 使用抗cd47抗体和抗cd20抗体的抗癌方案 |
| ES3007236T3 (en) * | 2018-09-04 | 2025-03-19 | Pfizer | Cd47 blockade with parp inhibition for disease treatment |
| CA3164623A1 (en) | 2019-12-17 | 2021-06-24 | Pfizer Inc. | Antibodies specific for cd47, pd-l1, and uses thereof |
| KR20220163447A (ko) * | 2020-04-06 | 2022-12-09 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체 제형 |
| WO2021259902A1 (en) * | 2020-06-22 | 2021-12-30 | Morphosys Ag | Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpα-cd47 innate immune checkpoint |
| CN117222413A (zh) * | 2021-02-10 | 2023-12-12 | 同润生物医药(上海)有限公司 | 治疗肿瘤的方法和组合 |
| CN115192718A (zh) * | 2021-04-14 | 2022-10-18 | 中山康方生物医药有限公司 | 抗cd47的单克隆抗体及其用途 |
| EP4353265A4 (en) * | 2021-06-10 | 2024-10-02 | ONO Pharmaceutical Co., Ltd. | METHOD OF TREATING CANCER BY MEANS OF A COMBINATION OF A CD47 INHIBITOR, AN IMMUNE CHECKPOINT INHIBITOR AND STANDARD THERAPY |
| CN115245516A (zh) * | 2021-12-31 | 2022-10-28 | 郑州大学第一附属医院 | 一种抗卵巢癌肿瘤药物联用方法、体外和体内验证方法 |
| WO2023172643A1 (en) * | 2022-03-08 | 2023-09-14 | Whitehead Institute For Biomedical Research | The combination of macrophage-directed immunotherapy and targeted agents for treatment of cancer |
| TWI876305B (zh) * | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2582340T3 (es) | 2008-01-15 | 2016-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Métodos para manipular fagocitosis mediada por CD47 |
| US20160095939A1 (en) | 2014-10-07 | 2016-04-07 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
| CA2771336C (en) | 2009-09-15 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
| WO2011041453A1 (en) | 2009-09-29 | 2011-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation and use of melanoma cancer stem cells |
| PT2569013T (pt) | 2010-05-14 | 2017-02-08 | Univ Leland Stanford Junior | Anticorpos monoclonais humanizados e quiméricos para cd47 |
| US20140271683A1 (en) | 2010-12-21 | 2014-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low Density Lipoprotein-Related Receptor |
| ES2816647T3 (es) | 2012-01-17 | 2021-04-05 | Univ Leland Stanford Junior | Reactivos SIRP-alfa de alta afinidad |
| BR112015013431A2 (pt) * | 2012-12-12 | 2017-11-14 | Vasculox Inc | anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos |
| CN112245586A (zh) | 2013-03-15 | 2021-01-22 | 小利兰·斯坦福大学托管委员会 | 用于实现治疗有效剂量的抗cd47剂的方法 |
| JP6843611B2 (ja) | 2013-04-29 | 2021-03-17 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 免疫を強化する抗ｃｄ４７因子の使用 |
| US9945870B2 (en) | 2013-05-17 | 2018-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining responsiveness to an anti-CD47 agent |
| CN106456749B (zh) | 2014-03-11 | 2021-03-30 | 小利兰·斯坦福大学托管委员会 | 抗SIRPα抗体和双特异性巨噬细胞增强型抗体 |
| WO2016023001A1 (en) | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| PT3177640T (pt) | 2014-08-08 | 2020-08-31 | Univ Leland Stanford Junior | Agentes pd-1 de alta afinidade e métodos de utilização |
| CA2959821C (en) | 2014-10-24 | 2024-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of MHC class I positive cells and for overcoming resistance to anti-CD47 agents/SIRPA |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| ES2761861T3 (es) | 2015-01-21 | 2020-05-21 | Univ Leland Stanford Junior | Uso de agonistas de TLR y agente anti-CD47 para mejorar la fagocitosis de las células cancerosas |
| US10358472B2 (en) | 2015-05-06 | 2019-07-23 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity CD47 analogs |
| US20180147257A1 (en) | 2015-05-22 | 2018-05-31 | The Board Of Trustees Of The Leland Stanford Junior University | Btn3a ectodomain proteins and methods of use |
| WO2017019767A1 (en) | 2015-07-27 | 2017-02-02 | Myosotis, Llc | Inhibition of CXCL12 in Cancer Immunotherapy |
| AU2016310348B2 (en) | 2015-08-26 | 2023-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist |
| RU2748401C2 (ru) * | 2015-09-18 | 2021-05-25 | Арч Онколоджи, Инк. | Терапевтические антитела к CD47 |
| CN108367073A (zh) | 2015-12-11 | 2018-08-03 | 小利兰·斯坦福大学托管委员会 | 以双重靶向cd47和egfr来治疗癌症 |
| JP2018538321A (ja) | 2015-12-28 | 2018-12-27 | シンダックス ファーマシューティカルズ，インコーポレイティド | 卵巣がんの処置のためのｈｄａｃ阻害剤および抗ｐｄ−ｌ１抗体の組合せ |
| PT3402820T (pt) * | 2016-01-11 | 2020-08-20 | Forty Seven Inc | Anticorpos monoclonais anti-cd47 quiméricos, de ratinho ou humanizados |
| US20170210803A1 (en) | 2016-01-21 | 2017-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with combinations of immunoregulatory agents |
| KR102505253B1 (ko) | 2016-04-15 | 2023-03-02 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법 |
| CN109862910A (zh) | 2016-08-03 | 2019-06-07 | 小利兰·斯坦福大学托管委员会 | 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效 |
| WO2018031419A1 (en) | 2016-08-12 | 2018-02-15 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for enhancing immunogenic cross-presentation of tumor antigens |
| EP3532497B1 (en) | 2016-10-26 | 2024-07-24 | The Board of Trustees of the Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| WO2018165015A1 (en) | 2017-03-09 | 2018-09-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of cd47 pathway |
| CN111315783A (zh) | 2017-10-18 | 2020-06-19 | 四十七公司 | 用抗cd47和抗pd-l1治疗卵巢癌 |
| JP7308191B2 (ja) | 2017-10-18 | 2023-07-13 | フォーティ セブン， インコーポレイテッド | 抗ｃｄ４７剤ベースの卵巣癌療法 |
| US20210213055A1 (en) | 2018-06-13 | 2021-07-15 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inducing phagocytosis |
| US20220091104A1 (en) | 2018-09-28 | 2022-03-24 | The Board Of Trustees Of The Leland Stanford Junior University | Analysis of polymorphisms in sirp-alpha for evaluating response to immunotherapy |
| WO2020160285A1 (en) | 2019-02-01 | 2020-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | SIRPα EXPRESSION ON T CELLS IS A BIOMARKER FOR FUNCTIONAL T CELLS DURING EXHAUSTION |
| WO2020163692A1 (en) | 2019-02-08 | 2020-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway |
-
2018
- 2018-10-18 JP JP2020522016A patent/JP7308191B2/ja active Active
- 2018-10-18 KR KR1020207014145A patent/KR102776457B1/ko active Active
- 2018-10-18 ES ES18800381T patent/ES2932286T3/es active Active
- 2018-10-18 ES ES22199536T patent/ES2989007T3/es active Active
- 2018-10-18 CN CN201880068424.8A patent/CN111247172B/zh active Active
- 2018-10-18 CN CN202311510416.3A patent/CN117771364A/zh active Pending
- 2018-10-18 AU AU2018351006A patent/AU2018351006B2/en active Active
- 2018-10-18 CA CA3078253A patent/CA3078253A1/en active Pending
- 2018-10-18 US US16/756,673 patent/US11802153B2/en active Active
- 2018-10-18 PT PT188003818T patent/PT3697817T/pt unknown
- 2018-10-18 PL PL18800381.8T patent/PL3697817T3/pl unknown
- 2018-10-18 PT PT221995368T patent/PT4177270T/pt unknown
- 2018-10-18 EP EP18800381.8A patent/EP3697817B1/en active Active
- 2018-10-18 SI SI201830808T patent/SI3697817T1/sl unknown
- 2018-10-18 WO PCT/US2018/056441 patent/WO2019079548A1/en not_active Ceased
- 2018-10-18 EP EP22199536.8A patent/EP4177270B1/en active Active
- 2018-10-18 PL PL22199536.8T patent/PL4177270T3/pl unknown
- 2018-10-18 SI SI201831145T patent/SI4177270T1/sl unknown
-
2022
- 2022-11-22 JP JP2022186406A patent/JP2023018062A/ja active Pending
-
2023
- 2023-09-27 US US18/373,655 patent/US20240150461A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500349A5 (https=) | ||
| Brosnan et al. | Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies | |
| Pinto et al. | Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) | |
| CN102223897B (zh) | 抗-vegf抗体与化学治疗联合用于治疗乳腺癌的应用 | |
| TWI619509B (zh) | 治療先前未經治療之ⅲ期或ⅳ期卵巢癌、輸卵管癌或原發性腹膜癌之卡鉑、太平洋紫杉醇與抗-vegf抗體之組合 | |
| Macaulay et al. | Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors | |
| JP2020059713A (ja) | 膠芽腫治療のための併用療法 | |
| EP3967306A1 (en) | Cancer treatments | |
| Pandey et al. | Engineered nanomaterials as an effective tool for HER2+ breast cancer therapy | |
| TW200838875A (en) | Combination therapy with angiogenesis inhibitors | |
| EP3446709A1 (en) | Combination therapy for the treatment of glioblastoma | |
| JP2021500336A5 (https=) | ||
| EP3553083A1 (en) | Combination therapy for the treatment of ovarian cancer | |
| JP2020506945A (ja) | がんの治療のための方法、組成物及びキット | |
| Koukourakis et al. | Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer | |
| KR20210084560A (ko) | Pd-1/pd-l1 신호전달 억제제에 반응하지 않는 암을 치료하기 위한 방법 및 약제 | |
| WO2005097086A2 (en) | Use of 5,10-methylene tetrahydrofolate for the treatment of cancer | |
| WO2012106379A1 (en) | Sensitization of cancer cells to treatment | |
| TW201109032A (en) | Anti-angiogenesis therapy for the treatment of previously treated breast cancer | |
| Miyata et al. | Current treatment landscape for patients with non–small cell lung cancer with common EGFR mutations | |
| JP2005511663A5 (https=) | ||
| George et al. | Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours | |
| US20210363253A1 (en) | Use of combined treatment of pd-1 antibody and apatinib for treating triple negative breast cancer | |
| RU2774721C2 (ru) | Применение комбинированного лечения на основе антитела к PD-1 и апатиниба для лечения трижды негативного рака молочной железы | |
| Bogaert et al. | Gastrointestinal cancer: Selection of clinically relevant drug-induced toxicities encountered in gastrointestinal cancer treatment |